Alza Expects Doxil-Hycamtin Ovarian Cancer Study Results To Drive Sales
Alza expects interim results from a Phase III trial comparing its liposomal doxorubicin product Doxil with SmithKline Beecham's Hycamtin (topotecan) in ovarian cancer will accelerate Doxil sales. The results will be presented at the American Society of Clinical Oncology meeting in New Orleans May 20.
You may also be interested in...
Accelerated approval Phase IV commitments for seven oncologic products will be reviewed at the March 12-13 meeting of FDA's Oncologic Drugs Advisory Committee
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011